Amgen Inc. (NASDAQ:AMGN) Shares Sold by Shufro Rose & Co. LLC

Shufro Rose & Co. LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 39,691 shares of the medical research company’s stock after selling 741 shares during the period. Amgen makes up 1.0% of Shufro Rose & Co. LLC’s portfolio, making the stock its 29th largest position. Shufro Rose & Co. LLC’s holdings in Amgen were worth $12,366,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Capital World Investors increased its position in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares during the period. GAMMA Investing LLC increased its position in Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after acquiring an additional 3,653,205 shares during the period. Capital International Investors increased its position in Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after acquiring an additional 3,495,503 shares during the period. Northern Trust Corp increased its position in Amgen by 15.8% in the 4th quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company’s stock valued at $1,676,183,000 after acquiring an additional 875,254 shares during the period. Finally, Capital Research Global Investors increased its position in Amgen by 20.7% in the 4th quarter. Capital Research Global Investors now owns 4,890,092 shares of the medical research company’s stock valued at $1,274,553,000 after acquiring an additional 839,686 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.76% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $295.10 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $340.89. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The stock’s 50 day moving average price is $291.53 and its 200 day moving average price is $291.66. The firm has a market cap of $158.68 billion, a P/E ratio of 26.93, a PEG ratio of 2.61 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the prior year, the company earned $3.96 EPS. Amgen’s revenue was up 9.4% on a year-over-year basis. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AMGN has been the topic of several recent analyst reports. Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Mizuho boosted their target price on Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 7th. UBS Group boosted their target price on Amgen from $315.00 to $326.00 and gave the stock a “neutral” rating in a research report on Monday, July 21st. Bank of America boosted their target price on Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research report on Wednesday, July 23rd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $307.27.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.